Trial Profile
Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy: A Multicenter Phase I Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Acronyms REMETY
- Sponsors AIO Studien gGmbH
- 25 Mar 2021 Status changed from recruiting to completed.
- 04 Jul 2020 Results (n=12) presented at the 22nd World Congress on Gastrointestinal Cancer
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium